TMOD3

Across TCGA pan-cancer cohorts, TMOD3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TMOD3 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher TMOD3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMOD3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and CCRCC show a favorable association.

UCEC, CCRCC, and LSCC are the cancer types where TMOD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Quartile	All	0.979	0.834	.024	10	view →
CCRCC	DFS	Tertile	IV	0.961	0.196	.024	8	view →
LSCC	OS	Tertile	All	0.961	1.000	.032	7	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	6	view →
GBM	DFS	Quartile	All	0.621	0.857	.016	4	view →
LUAD	DFS	Quartile	II,III,IV	0.734	0.931	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TMOD3–UCEC (DFS)

Open the UCEC breakdown →